Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EuroEyes International Eye Clinic Total Equity Chart
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EuroEyes International Eye Clinic (HKSE:01846) has a Total Equity of HK$1,284.5 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for EuroEyes International Eye Clinic and its competitors.
Is EuroEyes International Eye Clinic's Total Equity too high?
EuroEyes International Eye Clinic's current Total Equity is HK$1,284.5 Mil. Overall, EuroEyes International Eye Clinic has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does EuroEyes International Eye Clinic's Total Equity compare to HCA and THC?
EuroEyes International Eye Clinic's Total Equity of HK$1,284.5 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Healthcare Providers & Services company?
A good Total Equity depends on the Healthcare Providers & Services industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for EuroEyes International Eye Clinic and its competitors. EuroEyes International Eye Clinic's current Total Equity is HK$1,284.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EuroEyes International Eye Clinic stock overvalued right now?
Based on GuruFocus' analysis, EuroEyes International Eye Clinic (HKSE:01846) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$5.56, compared to a current price of HK$2.50 — trading 55% below its estimated fair value. The current Total Equity is HK$1,284.5 Mil. EuroEyes International Eye Clinic's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For EuroEyes International Eye Clinic (HKSE:01846), the current Total Equity is HK$1,284.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EuroEyes International Eye Clinic (HKSE:01846) Overvalued in 2026?
Based on GuruFocus' analysis, EuroEyes International Eye Clinic stock appears to be undervalued.
The current stock price of HK$2.50 is trading 55% below its estimated GF Value™ of HK$5.56.
GuruFocus considers EuroEyes International Eye Clinic to be Significantly Undervalued.
Key valuation signals for HKSE:01846:
Total Equity: HK$1,284.5 Mil
GF Value™: HK$5.56 vs. price of HK$2.50 (55% below fair value)
No single metric tells the full story. See the HKSE:01846 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EuroEyes International Eye Clinic Ltd is principally engaged in the provision of vision correction services in Germany, Denmark, the UK, the PRC including Hong Kong, and Switzerland. The Group is a high-end vision correction service provider in Germany, PRC, the UK, Denmark, and Switzerland. Its vision correction services include refractive laser surgery, phakic lens surgery (ICL), lens exchange surgery, and others including PRK/LASEK and ICRS implantation. Its revenue categories include provision of vision correction services generate maximum revenue, training services, sales of pharmaceutical products and others. The Group's five reportable segments are Germany generate maximum revenue, Denmark, UK, Chinese Mainland, and Switzerland.
83GF Score
Get the complete analysis for HKSE:01846
Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01846 has been successfully added to your 
